For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$10.22
Thesis
Telix Pharmaceuticals is a commercial radiopharmaceutical company built on an approved prostate cancer imaging agent. Diagnostic revenue funds a broadening therapeutic radioligand pipeline across oncology.
Catalysts
- Illuccix commercial growth
- Kidney and additional diagnostic approvals
- Therapeutic radioligand program advancement
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 21Financial resultsSEC
6-K filing containing Q2 2026 trading update for foreign issuer.
- Jul 2Trial initiationSEC
Telix Pharmaceuticals filed Form 6-K covering ProstACT GLOBAL P trial update.
- May 27Trial initiationClinicalTrials.gov
Phase 3 ProstACT Global trial (NCT06520345) of 177Lu-TLX591 + SOC vs SOC in mCRPC now recruiting
- May 15Trial readoutClinicalTrials.gov
Telix-sponsored trial NCT07238322 ([18F]FET PET glioma characterization) status updated to COMPLETED.
- May 14Trial initiationClinicalTrials.gov
Phase 1 trial NCT07197645 initiated for samarium analgesia in end-stage cancerous bone pain; recruiting status
- May 5Trial initiationClinicalTrials.gov
Phase 1b/2 trial (NCT05663710) of 177Lu girentuximab + cabozantinib + nivolumab in advanced clear cell RCC now recruiting; sponsor MD Anderson